

Suzen Medicare invests Rs 180 Cr to open IV fluid manufacturing facility in Hyderabad

12 January 2026 | News

The facility is production-ready and will manufacture IV fluids and antibiotics



Chief Minister of Telangana Revanth Reddy inaugurated Suzen Medicare's state-of-the-art IV fluid manufacturing facility at Maheshwaram (E-City), Hyderabad, marking another significant milestone in Telangana's expanding pharmaceutical and life sciences ecosystem.

Established with an investment of Rs 180 crore, the 1.60 lakh sq ft facility spread across four acres is production-ready and will manufacture IV fluids and antibiotics, catering to both domestic and global markets.

The unit has entered into a technology tie-up with Germany's Rommelag, a globally reputed leader in injectable packaging solutions—bringing advanced German manufacturing technology to Telangana.

Addressing the occasion, the Chief Minister highlighted the critical role of private investments in driving employment, industrial growth, and economic resilience, noting that Hyderabad's rise as a globally competitive city is the result of sustained effort over the past three decades.

He underlined that Suzen Medicare's investment aligns with the government's "Telangana Rising 2047" Vision, which aims to transform the State into a \$1 trillion economy by 2034 and a \$3 trillion economy by 2047. Both the Core Urban Region Economy (CURE)—focused on high-value services, innovation and technology—and the Peri Urban Region Economy (PURE)—driving large-scale manufacturing and industrial infrastructure—will play a pivotal role in achieving this ambition.

Reaffirming Telangana's leadership in pharmaceuticals, the Chief Minister noted that nearly 40% of India's bulk drug production originates from the State, with Hyderabad emerging as a global pharma and life sciences hub attracting international attention, talent, and investment.

With a focus on advanced manufacturing, global technology partnerships, and encouragement for young entrepreneurs,

Telangana continues to position itself as a preferred destination for next-generation pharma and healthcare investments.